These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16006879)

  • 1. Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study.
    Kopec JA; Goel V; Bunting PS; Neuman J; Sayre EC; Warde P; Levers P; Fleshner N
    J Urol; 2005 Aug; 174(2):495-9; discussion 499. PubMed ID: 16006879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam.
    Beemsterboer PM; de Koning HJ; Kranse R; Trienekens PH; van der Maas PJ; Schröder FH
    J Urol; 2000 Oct; 164(4):1216-20. PubMed ID: 10992369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of screening for prostate cancer: a nested case-control study.
    Concato J; Wells CK; Horwitz RI; Penson D; Fincke G; Berlowitz DR; Froehlich G; Blake D; Vickers MA; Gehr GA; Raheb NH; Sullivan G; Peduzzi P
    Arch Intern Med; 2006 Jan; 166(1):38-43. PubMed ID: 16401808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Misclassifying the indications for prostate-specific antigen testing may bias case-control studies of the efficacy of prostate cancer screening.
    Hoffman RM; Adams-Cameron ML; Murata GH
    J Clin Epidemiol; 2004 Oct; 57(10):1071-5. PubMed ID: 15528058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
    Bunting PS; Goel V; Williams JI; Iscoe NA
    CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program.
    Cohen L; Fouladi RT; Babaian RJ; Bhadkamkar VA; Parker PA; Taylor CC; Smith MA; Gritz ER; Basen-Engquist K
    Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):610-7. PubMed ID: 12869399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.
    Aus G; Bergdahl S; Lodding P; Lilja H; Hugosson J
    Eur Urol; 2007 Mar; 51(3):659-64. PubMed ID: 16934392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
    Lilja H; Ulmert D; Björk T; Becker C; Serio AM; Nilsson JA; Abrahamsson PA; Vickers AJ; Berglund G
    J Clin Oncol; 2007 Feb; 25(4):431-6. PubMed ID: 17264339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability of self-report versus chart-based prostate cancer, PSA, DRE and urinary symptoms.
    Sayre EC; Bunting PS; Kopec JA
    Can J Urol; 2009 Feb; 16(1):4463-71. PubMed ID: 19222884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
    Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of prostate cancer screening among health fair participants.
    Chiu BC; Anderson JR; Corbin D
    Public Health; 2005 Aug; 119(8):686-93. PubMed ID: 15949522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case-control prostate cancer screening studies should not exclude subjects with lower urinary tract symptoms.
    Godley PA; Carpenter WR
    J Clin Epidemiol; 2007 Feb; 60(2):176-80. PubMed ID: 17208124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
    J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
    Lim LS; Sherin K;
    Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden.
    Pilebro B; Johansson R; Damber L; Damber JE; Stattin P
    Scand J Urol Nephrol; 2003; 37(3):210-2. PubMed ID: 12775278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Japanese guideline for prostate cancer screening.
    Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T
    Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.